Macurek Libor, Lindqvist Arne, Medema René H
Department of Medical Oncology and Cancer Genomics Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Cancer Res. 2009 Jun 1;69(11):4555-8. doi: 10.1158/0008-5472.CAN-09-0142.
Overactivation of both Polo-like kinase-1 (Plk1) and Aurora-A is linked to cancer development, and small-molecule inhibitors that target these kinases are currently tested as anticancer drugs. Here, we discuss recent advances in the understanding of the functional crosstalk between Plk1 and Aurora-A before and during mitosis. Several recent findings have led to a better appreciation of how the activities of these distinct mitotic kinases are intertwined. Such insight is important for the expected utility of small-molecule inhibitors targeting Plk1 or Aurora-A, and it might help us to improve their application.
Polo样激酶1(Plk1)和Aurora-A的过度激活均与癌症发展相关,目前正在测试靶向这些激酶的小分子抑制剂作为抗癌药物。在此,我们讨论了在有丝分裂之前和期间对Plk1和Aurora-A之间功能串扰理解的最新进展。最近的几项发现使人们对这些不同的有丝分裂激酶的活性如何相互交织有了更好的认识。这种见解对于靶向Plk1或Aurora-A的小分子抑制剂的预期效用很重要,并且可能有助于我们改进它们的应用。